Business & Industry

Bristol Myers Squibb has expanded its ongoing strategic partnership with Schrödinger through a new agreement to deploy the agentic AI co-scientist platform, Bunsen, across its research operations. Building upon an established collaboration in which Bristol Myers Squibb already utilizes...

The Central Drugs Standard Control Organisation (CDSCO) has announced plans to launch the first phase of a comprehensive end-to-end digital drug regulatory platform within the next 18 months. Designed as a single-window interface for the Indian pharmaceutical industry, the...

The World Health Organization (WHO) has officially launched the first global framework intended to assist medicines regulators in advancing the development of greener pharmaceuticals while maintaining the highest standards of safety, quality, and efficacy. The document, titled "Towards a...

Merck has entered into seven voluntary licensing agreements with generic manufacturers to produce and distribute lower-cost versions of alimatravir, its experimental once-monthly oral HIV pill. The royalty-free agreements will cover both public and private sectors across 129 low- and...

President Donald Trump announced plans to implement massive generic drug tariffs starting at 100% in August 2028, scaling up to 200% in August 2029, in an effort to incentivize the pharmaceutical industry to move production to the United States. The...

Pharmaceutical giant Bristol Myers Squibb has announced the deployment of its second NVIDIA DGX SuperPOD, an advanced computing cluster designed to accelerate the drug discovery pipeline. This new infrastructure, which utilizes the Vera Rubin architecture, represents a significant commitment...

The Australian government is currently navigating a significant period of reassessment regarding its national drug reimbursement model, as tensions between global pharmaceutical manufacturers and health regulators reach a critical juncture. At the center of this dispute is the Pharmaceutical...